EP3565602B1 - Verfahren zur herstellung von wasserlöslichem forskolin - Google Patents

Verfahren zur herstellung von wasserlöslichem forskolin Download PDF

Info

Publication number
EP3565602B1
EP3565602B1 EP18700143.3A EP18700143A EP3565602B1 EP 3565602 B1 EP3565602 B1 EP 3565602B1 EP 18700143 A EP18700143 A EP 18700143A EP 3565602 B1 EP3565602 B1 EP 3565602B1
Authority
EP
European Patent Office
Prior art keywords
forskolin
cyclodextrin
complex
hydroxypropyl
specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18700143.3A
Other languages
English (en)
French (fr)
Other versions
EP3565602A1 (de
Inventor
Andreas Kubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scipharm SARL
Original Assignee
Scipharm SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm SARL filed Critical Scipharm SARL
Priority to SI201830296T priority Critical patent/SI3565602T1/sl
Priority to PL18700143T priority patent/PL3565602T3/pl
Priority to RS20210673A priority patent/RS61915B1/sr
Publication of EP3565602A1 publication Critical patent/EP3565602A1/de
Application granted granted Critical
Publication of EP3565602B1 publication Critical patent/EP3565602B1/de
Priority to HRP20210863TT priority patent/HRP20210863T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to a new method for preparing a complex of forskolin and cyclodextrin and inclusion complexes of forskolin and hydroxypropyl- ⁇ -cyclodextrins having a weight ratio of 1:0.2 to 1:4 (w/w).
  • Pharmaceutical compositions comprising said complex and their use are also provided.
  • Forskolin is a labdane diterpene that is produced by the Indian Coleus forskolii plant ( Plectranthus barbatus ). Forskolin is commonly used as a tool in biochemistry to raise levels of cyclic AMP (cAMP) in the study and research of cell physiology. Forskolin activates the enzyme adenylyl cyclase and increases intracellular levels of cAMP ( Metzger H. et al., 1981, Arzneiffenforschung, 1248-50 ). cAMP is an important second messenger necessary for the proper biological response of cells to hormones and other extracellular signals. It is required for cell communication in the hypothalamus/pituitary gland axis and for the feedback control of hormones. Cyclic AMP acts by activating cAMP-sensitive pathways such as protein kinase A and Epac.
  • cAMP cyclic AMP
  • Forskolin is a diterpene containing 2 ⁇ -hydroxyl groups at the 1-and 9-positions, a ⁇ -hydroxyl group at the 6-position and a ⁇ -acetoxy group at the 7-position with limited water solubility thus making it difficult to analyze forskolin activation curves and to use it for drug development.
  • Organic solvents have been shown to solubilize forskolin, however, said solvents can also inhibit the ability of forskolin to activate adenylate cyclase ( Huang R.D. et al., 1982, J.Cyclic.Nucleotide Res., 385-394 ).
  • Aqueous solutions of forskolin had also been produced by dissolving forskolin in solutions of hydroxypropyl- ⁇ -cyclodextrin.
  • Maximum solubility of forskolin was 2.5 mM and 9.8 mM in 40 % (w/v) aqueous solutions of hydroxypropyl- ⁇ -cyclodextrin and hydroxypropyl- ⁇ -cyclodextrin, respectively ( Laurenza A. et al., 1987, Molecular Pharmacology, 32:133-139 ). Thereby an increase of solubility of approx. 16-fold and approx. 65-fold was received.
  • Cyclodextrins are a family of cyclic oligosaccharides with a hydrophilic outer surface and a lipophilic central cavity. They consist of ( ⁇ -1,4)-linked ⁇ -D-glucopyranose units with a lipophilic central cavity. Due to the chair formation of the glucopyranose units, cyclodextrin molecules are shaped like cones with secondary hydroxyl groups extending from the wider edge and the primary groups from the narrow edge. Cyclodextrins are relatively large with a number of hydrogen donors and acceptors and do not permeate lipophilic membranes.
  • cyclodextrins have mainly been used as complexing agents to increase aqueous solubility of poorly soluble drugs, and to increase their bioavailability and stability ( Loftsson T., et al., 2005, Expert.Opin.Drug Deliv., 335-351 ).
  • the most common natural cyclodextrins consist of six (a-cyclodextrin), seven (B-cyclodextrin) and eight ( ⁇ -cyclodextrin) glucopyranose units. Further known natural cyclodextrins are ⁇ cyclodextrins. Random substitution of the hydroxyl groups can result in increased solubility. The main reason for solubility enhancement is that random substitution transforms the crystalline cyclodextrins into amorphous mixtures of isomeric derivatives.
  • Cyclodextrin derivatives include hydroxypropyl derivatives of ⁇ - and ⁇ -cyclodextrin, the randomly methylated ⁇ -cyclodextrin, sulfoburylether ⁇ -cyclodextrin and branched cyclodextrins such as glucosyl- ⁇ -cyclodextrin (Loftsson T. et al., 2005).
  • a 2-hydroxypropyl group will be connected to one or more hydroxyls of the cyclodextrin (HP-cyclodextrin).
  • a higher substitution of the hydroxyls with 2-hydroxypropyl also results in the formation of oligomeric hydroxypropylene oxide side chain formation.
  • a forskolin ⁇ -cyclodextrin complex is produced by adding forskolin to water containing dissolved hydroxypropyl- ⁇ -cyclodextrin, agitating the mixture and filtering it.
  • the object of the present invention is to provide a method for improved complexing of cyclodextrin and forskolin and to provide a forskolin complex with improved solubility but preserved structure.
  • an inclusion complex comprising forskolin and hydroxypropyl- ⁇ -cyclodextrin in a weight ratio of 1:0.2 to 1:4 (w/w), wherein forskolin and hydroxypropyl- ⁇ -cyclodextrin are comprised as an aqueous soluble complex.
  • the weight ratio of forskolin and hydroxypropyl- ⁇ -cyclodextrin is in the range of about 1:0.5 to 1:3.3 (w/w).
  • about 2.5 - 4.5 mg, specifically about 3 to 4 mg forskolin are present in 100 mg forskolin-cyclodextrin complex. Specifically about 2.5%, specifically about 3%, specifically about 3.5%, specifically about 3.7%, specifically about 4%, specifically about 4.5% (w/w), more specifically more than 5% (w/w) forskolin are present in the inclusion complex of the invention.
  • Forskolin cyclodextrin complex has approximately about 100 times, specifically about 120 times the solubility of native forskolin. It was also surprisingly shown that the native structure of forskolin is preserved when complexed with cyclodextrin and that the activation potential of forskolin for adenylyl cyclase is also preserved thus complexation with cyclodextrins does not reduce the activation.
  • the invention provides an administration formulation comprising an inclusion complex of the present invention together with suitable pharmaceutical auxiliaries.
  • composition comprising the inventive forskolin cyclodextrin inclusion complex, optionally together with further excipients, is provided.
  • the invention additionally provides a method of treating or preventing a condition treatable or preventable with forskolin, comprising administering to a subject in need of such treatment or prevention a pharmaceutically acceptable effective amount of a stable inclusion complex comprising forskolin and a cyclodextrin, specifically hydroxypropyl- ⁇ -cyclodextrin.
  • the present invention provides a method for preparing a forskolin cyclodextrin inclusion complex comprising the steps:
  • the cyclodextrin used in the method is selected from the group consisting of ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin (HP- ⁇ -CD), ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin (HP- ⁇ -CD), ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin (HP- ⁇ -CD), delta ( ⁇ )-cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin (HP- ⁇ -CD) and randomly methylated- ⁇ -cyclodextrin (RAMEB-CD).
  • ⁇ -cyclodextrin hydroxypropyl- ⁇ -cyclodextrin
  • HP- ⁇ -CD hydroxypropyl- ⁇ -cyclodextrin
  • RAMEB-CD randomly methylated- ⁇ -cyclodextrin
  • HP- ⁇ -CD, RAMEB-CD, and HP- ⁇ -CD provide significantly increased occupancy rates and are specifically used in the method described herein.
  • the heating temperature used in the method is about 220 °C.
  • the method is used for producing a powdered inclusion complex of forskolin and HP- ⁇ -cyclodextrin.
  • the solvent used in the present invention is an alcohol, specifically it is 2-propanol.
  • the precipitate is heat dried, specifically the drying step is carried out for about 1 to 30 minutes.
  • the precipitate is filtered, specifically by membrane filtration and optionally the precipitate is dried.
  • the term "complex” denotes an inclusion body complex, a non-inclusion body complex, a co-precipitate or a lyophilized complex. Preferably, it is a lyophilized complex or an inclusion complex.
  • Forskolin (Colforsin; 7-beta-acetoxy-8,13-epoxy-1-alpha, 6-beta, 9-alpha-trihydroxylabd-14-en-11-one; Coleonol) has the molecular formula C 22 H 34 O 7 and is of the structure as shown in Figure 1 .
  • forskolin also encompasses any congeners, analogs or derivatives of forskolin of natural or synthetic origin, which can be, but not limited to, isoforskolin, 7-deacetylforskolin, colforsin daropate hydrochloride, NKH477 ( Ito S. et al., 1993, Br.J.Pharmacol. 110(3), 1117-25 ), FSK88 ( Zhonghai L. et al., 2006, Cell Biol.Intern., 30(11), 940-946 ).
  • cyclodextrin refers to a cyclic dextrin molecule that is formed by enzyme conversion of starch. Cyclodextrins are cyclic oligosaccharides.
  • the cyclodextrins can be ⁇ -cyclodextrin, composed of a ring of six glucose residues; ⁇ -cyclodextrin, composed of a ring of seven glucose residues; ⁇ -cyclodextrin, composed of a ring of eight glucose units and ⁇ -cyclodextrin.
  • the inside cavity of a cyclodextrin is lipophilic, while the outside of the cyclodextrin is hydrophilic.
  • ⁇ -cyclodextrin is not known to have any toxic effects, is World-Wide GRAS (i.e., Generally Regarded As Safe), natural, and is FDA approved.
  • ⁇ -cyclodextrin and ⁇ -cyclodextrin are also considered natural products and are U.S and E.U. GRAS.
  • ⁇ -, ⁇ -or ⁇ -cyclodextrins prepared by the enzymatic conversion of starch differ in the diameter of their hydrophobic cavity and are generally suitable for inclusion of numerous lipophilic substances.
  • the use of cyclodextrins as excipients is also allowed by the European Medicines Agency (Background review for cyclodextrins used as excipients, Nov. 2014, EMA/CHMP/333892/2013).
  • a method for preparing a forskolin cyclodextrin inclusion complex comprising the sequential steps of:
  • solvent and water are simultaneously added to cyclodextrin and forskolin or the solvent can also be added before water is given to forskolin and cyclodextrin.
  • Solvents can be any organic or anorganic solvents like, but not limited to, alcohols, acetone, dichlormethane etc.. Alcohols are known to be useful solvents, specifically secondary alcohols like isopropyl alcohol (2-propanol), cyclohexanol. As an alternative, also primary alcohols can be used as solvents, e.g. methanol, ethanol, and butanol.
  • the heating of the mixture is performed at a temperature ranging from 200°C to 230°C, specifically ranging from 210°C to 225°C, specifically ranging from 215°C to 225°C more specifically at a temperature of about 220°C.
  • the heating is a sintering method, i.e heating forskolin and cyclodextrin without melting said components to the point of liquefaction.
  • the applicable sintering temperature can be determined by the skilled person without undue burden.
  • Forskolin has a melting point ranging from 230 to 232°C, therefore the upper limit of the heating procedure is at about 230°C.
  • Cyclodextrins have melting points ranging from 250 - 290°C depending on the type of cyclodextrin. As examples, the melting point of ⁇ -cyclodextrin is about 267°C, the melting point of ⁇ -cyclodextrin is about 260°C, the melting point of HP- ⁇ -cyclodextrin is about 250°C, and the melting point of HP- ⁇ -cyclodextrin is about 267°C.
  • the inclusion complex of the invention can be used for preparing a pharmaceutical composition.
  • Said inclusion complex is highly advantageous because currently available forskolin cyclodextrin complexes have a maximum occupancy of about 2% or less, whereas the present complex has a forskolin occupancy of ⁇ 2.5%, preferably ⁇ 3%, preferably ⁇ 3.5%, more preferably ⁇ 4% and can be provided as medical grade preparation.
  • an inclusion complex comprising forskolin and HP- ⁇ -cyclodextrin in a weight ratio of 1:0.2 to 1:4 (w/w), wherein forskolin and ⁇ -cyclodextrin are comprised as an aqueous soluble complex.
  • an inclusion complex comprising forskolin and HP- ⁇ -cyclodextrin in a weight ratio of 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:2.6, 1:2.7, 1:2.8, 1:2.9, 1:3, 1:3.1, 1:3.2, 1:3,3, 1:3.4, 1:3.5, 1:3.6, 1:3.7, 1:3.8, 1:3.9, or 1:4.
  • the forskolin cyclodextrin complex can be used for any dietary or medical purpose wherein soluble forskolin is applicable.
  • the specific dose of a complex administered according to this invention to obtain therapeutic or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the route of administration, the age, weight and response of the individual patient, the condition being treated and the severity of the patient's symptoms.
  • the complex containing the compound forskolin as active agent of the invention is most desirably administered at a concentration that will generally afford effective results without causing any serious side effects and can be administered either as a single unit dose, or if desired, the dosage may be divided into convenient subunits administered at suitable times throughout the day.
  • composition specifically comprises the forskolin cyclodextrin inclusion complex of the invention, optionally together with other excipients or agents.
  • compositions can be provided in a variety of systemic and topical formulations.
  • Systemic or topical formulations containing the inclusion complex of the invention are selected from the group of oral, intrabuccal, intrapulmonary, rectal, intrauterine, intradermal, topical, dermal, parenteral, intratumor, intracranial, intrapulmonary, buccal, sublingual, nasal, subcutaneous, intravascular, intrathecal, inhalable, respirable, intraarticular, intracavitary, implantable, transdermal, iontophoretic, intraocular, ophthalmic, vaginal, optical, intravenous, intramuscular, intraglandular, intraorgan, intralymphatic, slow release and enteric coating formulations.
  • the actual preparation and compounding of these different formulations is known in the art and need not be detailed here.
  • the composition may be administered once or several times a day.
  • Formulations suitable for respiratory, nasal, intrapulmonary, and inhalation administration are preferred, as are topical, oral and parenteral formulations.
  • the formulations are prepared by uniformly and intimately bringing forskolin presented as inclusion complex into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into desired formulations.
  • compositions suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing the composition as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • compositions suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the active compound, which preparations are preferably isotonic with the blood of the recipient. These preparations may contain antioxidants, buffers, bacteriostatic agents and solutes which render the compositions isotonic with the blood of the recipient.
  • Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents.
  • the compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried or lyophilized condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use.
  • Nasal and instillable formulations comprise purified aqueous solutions of the composition with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucous membranes.
  • composition disclosed according to the invention may be administered into the respiratory system either by inhalation, respiration, nasal administration or intrapulmonary instillation (into the lungs) of a subject by any suitable means, and are preferably administered by generating an aerosol or spray comprised of powdered or liquid nasal, intrapulmonary, respirable or inhalable particles.
  • the respirable or inhalable particles comprising the active compound are inhaled by the subject, e.g. by inhalation or by nasal administration or by instillation into the respiratory tract or the lung itself.
  • the formulation may comprise respirable or inhalable liquid or solid particles of the active compound that, in accordance with the present invention, include respirable or inhalable particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and continue into the bronchi and alveoli of the lungs.
  • respirable or inhalable particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and continue into the bronchi and alveoli of the lungs.
  • particles ranging from about 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 and 2 to about 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9., 9.5, 10 microns in diameter.
  • a particle size in the range of about 8, about 10, about 20, about 25 to about 35, about 50, about 100, about 150, about 250, about 500 ⁇ m in diameter is preferred to ensure retention in the nasal cavity or for instillation and direct deposition into the lung.
  • Liquid formulations may be squirted into the respiratory tract or nose and the lung, particularly when administered to newborns and infants.
  • Aerosols of liquid particles comprising the active compound may be produced by any suitable means, such as with a nebulizer.
  • Nebulizers are commercially available devices which transform solutions or suspensions of the active ingredient into a therapeutic aerosol mist either by means of acceleration of a compressed gas, typically air or oxygen.
  • Suitable compositions for use in nebulizer consist of the active ingredient in liquid carrier, the active ingredient comprising up to 40 % w/w composition, but preferably less than 20 % w/w carrier being typically water or a dilute aqueous alcoholic solution, preferably made isotonic with body fluids by the addition of, for example sodium chloride.
  • Optional additives include preservatives if the composition is not prepared sterile, for example, methyl hydroxybenzoate, antioxidants, flavoring agents, volatile oils, buffering agents and surfactants.
  • Aerosols of solid particles comprising the active compound may likewise be produced with any sold particulate medicament aerosol generator. Aerosol generators for administering solid particulate medicament, product particles which are respirable, as explained above, and generate a volume of aerosol containing a predetermined metered dose of a medicament at a rate suitable for human administration. Examples of such aerosol generators include metered dose inhalers and insufflators.
  • the delivery device comprises a dry powder inhalator (DPI) that delivers single or multiple doses of the composition.
  • DPI dry powder inhalator
  • the single dose inhalator may be provided as a disposable kit which is sterilely preloaded with enough formulation for one application.
  • the inhalator may be provided as a pressurized inhalator, and the formulation in a piercable or openable capsule or cartridge.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable excipients include starch, glucose, lactose, sucrose, gelatine, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin. The formulation should be selected according to the mode of administration.
  • the amount of the active drug in the inventive composition can be selected by any skilled person.
  • an effective amount refers to an amount effective to treat a disease, disorder, and/or condition, or to bring about a recited effect.
  • an effective amount can be an amount effective to reduce the progression or severity of the condition or symptoms being treated. Determination of a therapeutically effective amount is well within the capacity of persons skilled in the art, especially in light of the detailed disclosure provided herein.
  • the term “effective amount” is intended to include an amount of a compound described herein, or an amount of a combination of compounds described herein, e.g., that is effective to treat or prevent a disease or disorder, or to treat the symptoms of the disease or disorder, in a host.
  • an "effective amount” generally means an amount that provides the desired effect.
  • treating include (i) preventing a disease, pathologic or medical condition from occurring (e.g., prophylaxis); (ii) inhibiting the disease, pathologic or medical condition or arresting its development; (iii) relieving the disease, pathologic or medical condition; and/or (iv) diminishing symptoms associated with the disease, pathologic or medical condition.
  • the terms “treat”, “treatment”, and “treating” can extend to prophylaxis and can include prevent, prevention, preventing, lowering, stopping or reversing the progression or severity of the condition or symptoms being treated.
  • treatment can include medical, therapeutic, and/or prophylactic administration, as appropriate.
  • Forskolin is well known to be an unspecific cAMP activating agent.
  • the complex of the invention can be used for treating any disease or disorder that can be treated with forskolin.
  • Such disorders may be, but are not limited to, neurodegenerative diseases, Alzheimer disease, motoric dysfunctions, acute and chronic heart diseases, pulmonary diseases, like asthma, cystic fibrosis, vascular diseases associated with cystic fibrosis, bronchitis, chronic obstructive pulmonary disease (COPD), adipositas, fibrotic alterations like idiopathic pulmonary fibrosis, post-traumatic pulmonary fibrosis and Broncho-pulmonary dysplasia in preterm and term newborns, post toxic liver diseases like VOD or liver cirrhosis, peripheral circulation disorders including Raynaud's disease and sklerodermia.
  • Example 1 Synthesis of forskolin/cyclodextrin complex.
  • Forskolin a representative of the chemical group of diterpenes, is a largely water-insoluble plant constituent of Plectranthus barbatus (Coleus forskolii). Forskolin acts as adenylyl cyclase activator with a half-maximal effective concentration of about 10 ⁇ mol/l. Since the substance is largely water-insoluble, forskolin is dissolved in DMSO for use in assays. In order to avoid side effects of the solvent, forskolin is complexed with cyclodextrin in the present study and the thereby aycquired novel properties such as solubility in water are defined. Lastly, the adenylyl cyclase activity is checked.
  • Forskolin CD complexes are highly soluble in water and a comparable activation potential on the adenylyl cyclase could be determined:
  • the forskolin-CD complex activates the enzyme to the same extent as forskolin dissolved in DMSO.
  • Figure 1 shows the structure of forskolin and binding sites to the C1 and C2 domain of adenylyl cyclase.
  • the two OH-groups (marked in red) are essential for binding and must not be derivatized for these applications.
  • Cyclodextrin (CD) Hydroxypropyl- ⁇ -CD from Fluka 56334. Since hydroxypropyl derivatives are also permitted in the pharmaceutical field, these derivatives were also used. Furthermore, HP- ⁇ -CD was purchased from Ashland (Wacker Chemie): trade name "Cavasol", batch: A1603A0012. RAMEB-CD is from Cyclolab R&D Ltd. Hungary, batch: CYL-4152.
  • Forskolin an enriched extract (presumably CO2 extraction) from Sabinsa (www.sabinsaeuroope.com) Lot. C30698, with a content of 95% forskolin was used, which had been purified to over 98.5% in the course of the present project.
  • the GMP quality of forskolin from MercaChem (batch: MAMA07-024-5,> 99.7% HPLC) was used.
  • powder or fine-grained materials were heated at temperatures below the melting temperature of the main components forskolin and cyclodextrin.
  • the melting point of forskolin is at about 230°C
  • the melting point or decomposition point of the cyclodextrins is at about 260°C. If the mixture forskolin-CD was not heated above 220°C, the components were retained. Temperatures above 230°C gave the matrix a brownish color indicating material changes.
  • the content of forskolin with 3 -4 mg per 100 mg of forskolin-CD complex is to be indicated as follows: 3-4% (weight/weight) of the forskolin cyclodextrin complex (forskolin CD).
  • 100 mg of forskolin CD was readily soluble in 2 ml of water, which is equivalent to 50 g per liter. Maximum solubility may even be higher.
  • the forskolin CD complex was very readily soluble in water.
  • the content of forskolin was determined by HPLC, the parameters were described above.
  • CD molecules which are hydrophilic on the outside, were directly present in the elution profile after the injection peak (column is doped with an octadecyl phase, C18 reversed phase). Forskolin showed a retention time of 8 minutes.
  • the content of forskolin should be indicated with a maximum of 4.7 mg per 100 mg forskolin-CD complex.
  • the maximum solubility of the forskolin-CD complex has not yet been determined since large quantities of material are required. Once the final product is received, the maximum solubility will be determined. However, 100 mg, up to 500 mg of forskolin-CD per mL of water were readily soluble, equivalent to 100 g (500 g) per liter.
  • the method was performed at the Institute of Pharmacology, Medical University 10 of Vienna, Prof. Michael Freissmuth.
  • the forskolin-CD complex was compared with an established method, where forskolin is dissolved and diluted in DMSO.
  • the method has been described previously ( Hussain F, et al., BMC Pharmacology 11 (2013), Suppl 2, A6 ) and is a test platform for the assessment of the chemical induction of stem cells.
  • Figure 3 shows the cAMP assay for forskolin dissolved in DMSO and forskolin-15 CD complex, according to Hussain et al., 2013.
  • F-CD 116 400 mg HP-y-CD, 32 mg forskolin, 45°C 1h + 72h RT); F-CD 118 (500 mg HP-y-CD, 105 mg forskolin, 40°C 3h + 72h RT), F-CD 119 (500 mg HP- ⁇ -CD, 105 mg forskolin, 40°C 3h + 72h RT), F-CD 130 (80 mg HP- ⁇ -CD, 60 mg forskolin, 165-210 °C, 100 ⁇ L H 2 O, 50 ⁇ L Propanol), F-CD 138 (80 mg HP- ⁇ -CD, 60 mg forskolin, 140-220°C, 100 ⁇ L H 2 O, 50 ⁇ L Propanol, citr.), F-CD 140 (240 mg HP- ⁇ -CD, 180 mg forskolin, 200-228 °C, 300 ⁇ L H2O, 150 ⁇ L Propanol, LYO).
  • Figure 4 shows a cAMP assay for forskolin dissolved in DMSO and forskolin-CD complex, according to Husain et al. (BMC Pharmacol. 11 (2013(, Suppl 2:A6 . ⁇ -CD and ⁇ -CD are compared herein. It is shown that there is no significant difference between forskolin dissolved in DMSO and forskolin ⁇ -CD complex which proves that activity of forskolin complex bound in CD is not diminished, compared to forskolin dissolved in DMSO.
  • Forskolin- ⁇ -CD activates the adenylyl cyclase slightly weaker. Inactive regarding the adenylyl cyclase are the control samples of pure cyclodextrins without forskolin, as well as the alternative diterpenes salvinorin A and salvinorin B.
  • the inner diameter of ⁇ -CD is 9.5 ⁇ (see Table 2), the width of the native forskolin molecule is about 8 ⁇ (own calculation via the "ligand scout" program, Inte:ligand GmbH ; length approx. 10.5 ⁇ , widest point about 8 ⁇ .
  • Table 2 Properties of natural cyclodextrins (CD) (8). Properties ⁇ -CD ⁇ -CD ⁇ -CD ⁇ -CD Glucose units 6 7 8 9 Molar mass (G/Mol) 972 1135 1297 Inner diameter ( ⁇ ) 5.7 7.8 9.5 Size of the hollow space ( ⁇ ) 7.8 7.8 7.8 Water solubility (q/L) RT 145 18,5 232
  • HP- ⁇ -CD, RAMEB-CD, and HP- ⁇ -CD show significantly increased occupancy rate.

Claims (12)

  1. Verfahren zur Herstellung eines Forskolin-Cyclodextrin-Einschlusskomplexes, umfassend die folgenden Schritte:
    a) Mischen von Forskolin und Cyclodextrin in einem Gewichtsverhältnis von 1:0,5 bis 1:4,
    b) Zugeben von Wasser und Lösungsmittel, um ein Gemisch zu bilden,
    c) Erhitzen des Gemischs bei einer Temperatur im Bereich von 180 °C bis 230 °C,
    spezifisch im Bereich von 200 bis 230 °C, im Bereich von 210 bis 220 °C, insbesondere bei etwa 220 °C,
    d) Zugeben von Wasser zu dem Gemisch, gefolgt von Mischen und Ausfällenlassen des Gemischs,
    e) Isolieren des Präzipitats von dem Gemisch und gegebenenfalls Trocknen des Präzipitats.
  2. Verfahren gemäß Anspruch 1, wobei das Cyclodextrin ausgewählt ist aus der Gruppe bestehend aus α-Cyclodextnn, Hydroxypropyl-α-cyclodextrin, β-Cyclodextrin, γ-Cyclodextrin.
  3. Verfahren gemäß Anspruch 1 oder 2, wobei das Cyclodextrin ausgewählt ist aus der Gruppe bestehend aus Hydroxypropyl-β-cyclodextrin, Hydroxypropyl-γ-cyclodextrin und RAMEB-CD.
  4. Verfahren gemäß einem der Ansprüche 1 bis 3, wobei die Erhitzungstemperatur 210 °C oder 220 °C ist.
  5. Verfahren gemäß einem der Ansprüche 1 bis 4 zur Herstellung eines pulverisierten Einschlusskomplexes aus Forskolin und HP-γ-cyclodextrin.
  6. Verfahren gemäß einem der Ansprüche 1 bis 5, wobei das Lösungsmittel Alkohol ist und insbesondere 2-Propanol ist.
  7. Verfahren gemäß einem der Ansprüche 1 bis 6, wobei das Wärmetrocknen für etwa 1 bis 30 Minuten durchgeführt wird.
  8. Verfahren gemäß einem der Ansprüche 1 bis 7, wobei das Präzipitat filtriert wird, insbesondere durch Membranfiltration.
  9. Verfahren gemäß einem der Ansprüche 1 bis 8, wobei das Präzipitat bei Raumtemperatur getrocknet wird.
  10. Einschlusskomplex, umfassend γ-Cyclodextrin und Forskolin in einem Gewichtsverhältnis von 1:0,2 bis 1:4 (w/w), wobei das γ-Cyclodextrin Hydroxypropyl-γ-cyclodextrin ist.
  11. Einschlusskomplex gemäß Anspruch 10, wobei das Gewichtsverhältnis von Forskolin und Hydroxypropyl-γ-cyclodextrin im Bereich von 1:0,5 bis 1:3,3 (w/w) liegt.
  12. Pharmazeutische Zusammensetzung, enthaltend einen Einschlusskomplex gemäß einem der Ansprüche 10 oder 11.
EP18700143.3A 2017-01-09 2018-01-09 Verfahren zur herstellung von wasserlöslichem forskolin Active EP3565602B1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SI201830296T SI3565602T1 (sl) 2017-01-09 2018-01-09 Nov postopek za pripravo vodotopnega forskolina
PL18700143T PL3565602T3 (pl) 2017-01-09 2018-01-09 Nowy sposób wytwarzania rozpuszczalnej w wodzie forskoliny
RS20210673A RS61915B1 (sr) 2017-01-09 2018-01-09 Novi postupak za pripremu forskolina rastvorljivog u vodi
HRP20210863TT HRP20210863T1 (hr) 2017-01-09 2021-05-31 Novi postupak za pripremu forskolina topivog u vodi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17150644 2017-01-09
PCT/EP2018/050447 WO2018127600A1 (en) 2017-01-09 2018-01-09 Novel process for preparing water soluble forskolin

Publications (2)

Publication Number Publication Date
EP3565602A1 EP3565602A1 (de) 2019-11-13
EP3565602B1 true EP3565602B1 (de) 2021-03-03

Family

ID=57868023

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18700143.3A Active EP3565602B1 (de) 2017-01-09 2018-01-09 Verfahren zur herstellung von wasserlöslichem forskolin

Country Status (17)

Country Link
US (1) US11234957B2 (de)
EP (1) EP3565602B1 (de)
JP (1) JP7138643B2 (de)
KR (1) KR102583356B1 (de)
CN (1) CN110325217B (de)
CY (1) CY1124325T1 (de)
DK (1) DK3565602T3 (de)
ES (1) ES2872223T3 (de)
HR (1) HRP20210863T1 (de)
HU (1) HUE054617T2 (de)
LT (1) LT3565602T (de)
PL (1) PL3565602T3 (de)
PT (1) PT3565602T (de)
RS (1) RS61915B1 (de)
SG (1) SG11201906321WA (de)
SI (1) SI3565602T1 (de)
WO (1) WO2018127600A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023511432A (ja) 2020-01-23 2023-03-17 サイファーム ソシエテ ア レスポンサビリテ リミテ ７－デアセチル－フォルスコリンとｐｖｐの複合体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU199444B (en) 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
JP3040015B2 (ja) 1991-08-21 2000-05-08 日研化学株式会社 フォルスコリンの包接化合物
IT1294205B1 (it) 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
US6884885B2 (en) * 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
GB0127677D0 (en) * 2001-11-19 2002-01-09 Vianex S A Inclusion complex
KR101195114B1 (ko) 2003-05-20 2012-10-25 (주)하야시바라 생물화학연구소 수 가용성 이소플라본 조성물 및 그 제조 방법 및 그 용도
US6960300B2 (en) 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
WO2006013039A2 (en) * 2004-08-02 2006-02-09 Chiesi Farmaceutici S.P.A. A process for the preparation of a piroxicam: beta­cyclodextrin inclusion compound
BRPI0705319A2 (pt) * 2007-07-23 2009-07-21 Uniao Brasileira De Educacao Manedora Da Pucrs processo para obtenção de um complexo solúvel de resveratrol e/ou seus derivados; complexo de resveratrol e/ou seus derivados; composição nutracêutica
EP2253627A1 (de) 2009-05-21 2010-11-24 ERREGIERRE S.p.A. Einschlusskomplex für Raloxifen-Hydrochlorid und beta-Cyclodextrin
CN103768616B (zh) * 2014-01-08 2015-08-05 中国科学院昆明植物研究所 毛萼乙素环糊精包合物、含有该包合物的药物组合物、其制备方法及应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
HUE054617T2 (hu) 2021-09-28
PT3565602T (pt) 2021-05-26
SI3565602T1 (sl) 2021-07-30
JP2020505339A (ja) 2020-02-20
JP7138643B2 (ja) 2022-09-16
US20210145791A1 (en) 2021-05-20
EP3565602A1 (de) 2019-11-13
WO2018127600A1 (en) 2018-07-12
KR20190107690A (ko) 2019-09-20
HRP20210863T1 (hr) 2021-08-20
SG11201906321WA (en) 2019-08-27
CN110325217B (zh) 2023-08-08
DK3565602T3 (da) 2021-06-07
ES2872223T3 (es) 2021-11-02
KR102583356B1 (ko) 2023-09-26
CY1124325T1 (el) 2022-07-22
LT3565602T (lt) 2021-06-25
RS61915B1 (sr) 2021-06-30
US11234957B2 (en) 2022-02-01
CN110325217A (zh) 2019-10-11
PL3565602T3 (pl) 2021-09-13

Similar Documents

Publication Publication Date Title
Jansook et al. Cyclodextrins: Structure, physicochemical properties and pharmaceutical applications
EP0865789B1 (de) Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
EP1476473B1 (de) Neue komplexe natürlicher cyclodextrine
EP1476472B1 (de) Neue komplexe methylierter cyclodextrine
JPH0570612B2 (de)
JP5021305B2 (ja) 水溶性ジテルペンの調製方法およびその適用
JP2004525104A (ja) モダフィニルおよびシクロデキストリンの複合体
Agrawal et al. Cyclodextrins—a review on pharmaceutical application for drug delivery
US6077871A (en) Droloxifene pharmaceutical compositions
EP3565602B1 (de) Verfahren zur herstellung von wasserlöslichem forskolin
US8034371B2 (en) Intranasal compositions
EP0399716B1 (de) Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung
WO2016110193A1 (zh) 一种水飞蓟宾注射剂及其制备方法
US8293749B2 (en) Injectable meclizine formulations and methods
EP2561863A1 (de) Pharmazeutische Zusammensetzungen mit Voriconazol
JP3040015B2 (ja) フォルスコリンの包接化合物
Fernandes Studying the formation of self-aggregates of thiolated cyclodextrins and dexamethasone solution for aerosols
CN114099443A (zh) 一种奥司他韦药物组合物及其制备方法和用途
KR920008700B1 (ko) 수-난용성 또는 수-불안정성 약제와 β-사이클로덱스트린 에테르의 수용성 복합체의 제조방법
RU2575793C2 (ru) Липосома, имеющая внутреннюю водную фазу, содержащую соль сульфобутилового эфира циклодекстрина

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190730

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602018013354

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0047400000

Ipc: A61P0043000000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101AFI20200821BHEP

Ipc: A61K 31/352 20060101ALI20200821BHEP

INTG Intention to grant announced

Effective date: 20200930

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SCIPHARM S.A R.L.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1366561

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210315

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018013354

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 3565602

Country of ref document: PT

Date of ref document: 20210526

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20210518

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20210863T

Country of ref document: HR

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210604

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 37241

Country of ref document: SK

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E020826

Country of ref document: EE

Effective date: 20210526

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20210401410

Country of ref document: GR

Effective date: 20210709

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20210303

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20210863

Country of ref document: HR

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E054617

Country of ref document: HU

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2872223

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211102

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018013354

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210863

Country of ref document: HR

Payment date: 20220104

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210303

26N No opposition filed

Effective date: 20211206

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1366561

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210303

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210863

Country of ref document: HR

Payment date: 20221229

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20230123

Year of fee payment: 6

Ref country code: FR

Payment date: 20230124

Year of fee payment: 6

Ref country code: DK

Payment date: 20230123

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230106

Year of fee payment: 6

Ref country code: SE

Payment date: 20230119

Year of fee payment: 6

Ref country code: LV

Payment date: 20230115

Year of fee payment: 6

Ref country code: IT

Payment date: 20230120

Year of fee payment: 6

Ref country code: BE

Payment date: 20230119

Year of fee payment: 6

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20210863

Country of ref document: HR

Payment date: 20231228

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20231222

Year of fee payment: 7

Ref country code: RS

Payment date: 20231229

Year of fee payment: 7

Ref country code: RO

Payment date: 20231228

Year of fee payment: 7

Ref country code: PT

Payment date: 20231221

Year of fee payment: 7

Ref country code: MT

Payment date: 20231222

Year of fee payment: 7

Ref country code: LT

Payment date: 20231222

Year of fee payment: 7

Ref country code: HR

Payment date: 20231228

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231228

Year of fee payment: 7

Ref country code: NL

Payment date: 20240119

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240119

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240122

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240110

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240227

Year of fee payment: 7

Ref country code: IE

Payment date: 20240119

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240122

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240123

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210303

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240123

Year of fee payment: 7

Ref country code: FI

Payment date: 20240119

Year of fee payment: 7

Ref country code: EE

Payment date: 20240116

Year of fee payment: 7

Ref country code: DE

Payment date: 20240119

Year of fee payment: 7

Ref country code: CZ

Payment date: 20231229

Year of fee payment: 7

Ref country code: CY

Payment date: 20240105

Year of fee payment: 7

Ref country code: BG

Payment date: 20240122

Year of fee payment: 7

Ref country code: GB

Payment date: 20240123

Year of fee payment: 7

Ref country code: SK

Payment date: 20240104

Year of fee payment: 7

Ref country code: CH

Payment date: 20240202

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20231228

Year of fee payment: 7